



# New Hampshire Medicaid Fee-for-Service (FFS) Program

## Prior Authorization Drug Approval Form

Weight Management Medications

DATE OF MEDICATION REQUEST:     /     /

### SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

GENDER: ☐ Male ☐ Female

Drug Name

Strength

Dosing Directions

Length of Therapy

### SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FAX NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

### SECTION III: CLINICAL HISTORY

For Imcivree™ requests, skip to question 16.

1. Patient's diagnosis: \_\_\_\_\_

2. Is the patient between 12 and 18 years of age (Saxenda®, Wegovy®, Xenical® only)?

☐ Yes ☐ No

If **yes**, skip to **question 11**.

3. Is the patient 16 years of age or older (phentermine, Lomaira™) or 18 years of age or older (all drugs)?

☐ Yes ☐ No

4. Has the patient failed to lose weight on a low-calorie diet (1,200 kcal/day for women, 1,600 kcal/day for men) **and** exercise regimen after at least a 3-month trial?

☐ Yes ☐ No

Explain: \_\_\_\_\_

5. Does the patient have a body mass index (BMI) of 30 kg/m<sup>2</sup> or more with no risk factors or 27 kg/m<sup>2</sup> or more with at least one high-risk factor or two other risk factors?

☐ Yes ☐ No

6. Patient's BMI: \_\_\_\_\_ Weight: \_\_\_\_\_ Height: \_\_\_\_\_ Date: \_\_\_\_\_

Phone: 1-866-675-7755

Fax: 1-888-603-7696

© 2021–2025 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Revision Date: 06/05/2025





**New Hampshire Medicaid Fee-for-Service (FFS) Program**  
**Prior Authorization Drug Approval Form**  
Weight Management Medications

**PATIENT LAST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**PATIENT FIRST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (*continued*)**

7. Waist Circumference: \_\_\_\_\_
8. Does the patient have any of the following **high-risk** factors? (Check all that apply.)  
☐ Sleep apnea    ☐ Coronary heart disease    ☐ Type 2 diabetes    ☐ Atherosclerotic disease
9. Does the patient have any of the following risk factors? (Check all that apply.)  
☐ Hypertension    ☐ Gynecologic abnormalities    ☐ Cigarette smoking    ☐ Osteoarthritis    ☐ Gallstones  
☐ Dyslipidemia    ☐ Family history of premature heart disease    ☐ Impaired fasting glucose concentration  
☐ Age (men more than 45 years, women more than 55 years or postmenopausal)    ☐ Stress incontinence
10. Are there any contraindications to the use of this drug for this patient? ☐ Yes ☐ No  
If **yes**, explain then **skip to question 21:** \_\_\_\_\_
11. Is the patient's body weight more than 60 kg? ☐ Yes ☐ No
12. Does the patient's initial BMI correspond to 30 kg/m<sup>2</sup> for adults? ☐ Yes ☐ No
13. Is the patient higher than the 95th percentile on the pediatric growth chart? ☐ Yes ☐ No
14. Will the patient be maintained on a reduced calorie diet and increased physical activity? ☐ Yes ☐ No
15. Are there any contraindications to the use of this drug for this patient? ☐ Yes ☐ No  
If **yes**, explain, then **skip to question 21:** \_\_\_\_\_
16. Does the patient have a BMI 30 kg/m<sup>2</sup> or more or in the 95th or higher percentile on the pediatric growth chart? ☐ Yes ☐ No
17. Does the patient have a diagnosis of proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, as confirmed by a genetic test? ☐ Yes ☐ No
18. Is the genetic variant pathogenic, likely pathogenic, or of uncertain significance? ☐ Yes ☐ No
19. Does the patient have a diagnosis of Bardet-Biedl Syndrome? **If yes, select all that apply.** ☐ Yes ☐ No  
☐ Intellectual impairment    ☐ Renal anomalies    ☐ Polydactyly  
☐ Retinal degeneration    ☐ Genital anomalies
20. Is the prescriber an endocrinologist or geneticist, or has one been consulted? ☐ Yes ☐ No
21. Is there any additional information that would help in the decision-making process?  
If additional space is needed, please use a separate sheet.



**New Hampshire Medicaid Fee-for-Service (FFS) Program**  
**Prior Authorization Drug Approval Form**  
Weight Management Medications

**PATIENT LAST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--

**PATIENT FIRST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (*continued*)**

Baseline body weight: \_\_\_\_\_ Renewal body weight: \_\_\_\_\_

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

**PRESCRIBER'S SIGNATURE:** \_\_\_\_\_ **DATE:** \_\_\_\_\_